Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IRD
stocks logo

IRD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent
Wall Street analysts forecast IRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRD is 8.00 USD with a low forecast of 6.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast IRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRD is 8.00 USD with a low forecast of 6.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.230
sliders
Low
6.00
Averages
8.00
High
9.00
Current: 2.230
sliders
Low
6.00
Averages
8.00
High
9.00
Piper Sandler
Overweight
initiated
$7
2025-11-25
Reason
Piper Sandler
Price Target
$7
2025-11-25
initiated
Overweight
Reason
Piper Sandler initiated coverage of Opus Genetics with an Overweight rating and $7 price target. The company has demonstrated early efficacy data for its lead gene therapy program, OPGx-LCA5, in Leber congenital amaurosis type 5, where there are currently no treatment options and a high unmet need, the analyst tells investors in a research note. In addition, Piper says Opus' second gene therapy program, OPGx-BEST1 for BEST1-related inherited retinal diseases, has promising preclinical data.
Wedbush
Yun Zhong
Outperform
initiated
$8
2025-10-29
Reason
Wedbush
Yun Zhong
Price Target
$8
2025-10-29
initiated
Outperform
Reason
As previously reported, Wedbush analyst Yun Zhong initiated coverage of Opus Genetics with an Outperform rating and $8 price target. The October 2024 deal to combine the previous private Opus with Ocuphire "created a unique company with two distinctive approaches and a strong focus on ophthalmology indications," the analyst tells investors in a research note. The firm sees an over $10B market opportunity for Opus' gene therapy portfolio. It believes clinical and regulatory updates in in the coming months will serve as "strong catalysts" to drive continued share outperformance.
Wedbush
NULL -> Outperform
initiated
$8
2025-10-29
Reason
Wedbush
Price Target
$8
2025-10-29
initiated
NULL -> Outperform
Reason
Wedbush initiated coverage of Opus Genetics with an Outperform rating and $8 price target.
Chardan
NULL -> Buy
initiated
$9
2025-10-16
Reason
Chardan
Price Target
$9
2025-10-16
initiated
NULL -> Buy
Reason
Chardan initiated coverage of Opus Genetics with a Buy rating and $9 price target. The firm cites the commercial potential of the company's gene therapy assets, including OPGx-LCA5 for Leber congenital amaurosis type 5 and OPGx-BEST1 for bestrophinopathies, along with additional upside potential from its partnered phentolamine small molecule programs for the Buy rating.
Lucid Capital
Dev Prasad
Buy
initiated
$5
2025-06-18
Reason
Lucid Capital
Dev Prasad
Price Target
$5
2025-06-18
initiated
Buy
Reason
Craig-Hallum
Albert Lowe
Strong Buy
Initiates
$6
2025-04-11
Reason
Craig-Hallum
Albert Lowe
Price Target
$6
2025-04-11
Initiates
Strong Buy
Reason
Craig-Hallum analyst Albert Lowe initiated coverage of Opus Genetics with a Buy rating and $6 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Opus Genetics Inc (IRD.O) is -4.90, compared to its 5-year average forward P/E of -1.96. For a more detailed relative valuation and DCF analysis to assess Opus Genetics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.96
Current PE
-4.90
Overvalued PE
-0.75
Undervalued PE
-3.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.03
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.15
Undervalued EV/EBITDA
-0.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.27
Current PS
0.00
Overvalued PS
6.87
Undervalued PS
1.67
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 892.48% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 2167.49% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 892.48% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

IRD News & Events

Events Timeline

(ET)
2025-12-01
09:00:00
Brookline Initiates Coverage of Opus Genetics with Buy Rating and $8 Price Target
select
2025-11-13 (ET)
2025-11-13
07:13:54
Opus Genetics administers first dose to participant in OPGx-BEST1 Phase 1/2 trial
select
2025-11-12 (ET)
2025-11-12
07:08:39
Opus Genetics announces Q3 earnings per share of 25 cents, compared to a loss of 29 cents in the previous year.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-03Globenewswire
Opus Genetics Grants 124,000 Stock Options to Attract New Employees
  • Employee Incentive Plan: Opus Genetics' Compensation Committee approved the grant of 124,000 stock options to two new employees as a significant measure to attract talent, aiming to enhance the company's appeal in the competitive biopharmaceutical industry.
  • Compliance Assurance: The equity awards comply with Nasdaq Listing Rule 5635(c)(4), ensuring transparency for awards made outside of stockholder-approved equity plans, thereby enhancing corporate governance standards.
  • Long-term Incentive Mechanism: The options will vest over four years, with 25% vesting in the first year and the remaining 75% vesting quarterly, designed to boost employee loyalty and engagement through a long-term incentive structure.
  • Strategic Development Focus: Opus Genetics focuses on developing gene therapies for inherited retinal diseases, and this equity incentive plan will help attract key talent to accelerate the development of its innovative drug pipeline.
[object Object]
Preview
5.0
12-03Newsfilter
Opus Genetics Approves 124,000 Stock Options as Employee Incentives
  • Incentive Plan Approval: Opus Genetics' Compensation Committee approved 124,000 stock options as incentives for two new employees, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in gene therapy.
  • Compliance Assurance: The stock options granted comply with Nasdaq Listing Rule 5635(c)(4), ensuring transparency and compliance in attracting non-executive employees, which boosts investor confidence.
  • Long-term Incentive Structure: The options will vest over four years, with 25% vesting in the first year and the remaining 75% in quarterly installments, a structure that not only incentivizes long-term employee retention but also aligns their interests with the company's performance, promoting overall growth.
  • R&D Focus: Opus Genetics is dedicated to developing gene therapies for inherited retinal diseases, and with the addition of new employees, the company is expected to accelerate the advancement of its seven AAV-based programs, further solidifying its position in the biopharmaceutical industry.
[object Object]
Preview
4.0
11-22TipRanks
Top Analysts Recommend Purchasing These 3 Penny Stocks Immediately

  • Investment Opportunities: Five-star Wall Street analysts have identified several penny stocks as Buys, suggesting significant potential gains from current price levels.

  • Quantum-Si (QSI): This biotechnology company focuses on protein sequencing technology, with a Buy rating and a price target of $4, indicating a potential upside of over 222%.

  • Opus Genetics (IRD): A clinical-stage biopharmaceutical company targeting eye disorders, it has a Buy rating and a price target of $6, suggesting an upside of more than 210%.

  • Dakota Gold Corp (DC): Engaged in mineral property exploration, particularly for gold, it has a Buy rating with a price target of $14, representing a potential upside of over 256%.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Opus Genetics Inc (IRD) stock price today?

The current price of IRD is 2.23 USD — it has increased 6.7 % in the last trading day.

arrow icon

What is Opus Genetics Inc (IRD)'s business?

Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.

arrow icon

What is the price predicton of IRD Stock?

Wall Street analysts forecast IRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRD is 8.00 USD with a low forecast of 6.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Opus Genetics Inc (IRD)'s revenue for the last quarter?

Opus Genetics Inc revenue for the last quarter amounts to 3.08M USD, decreased -20.38 % YoY.

arrow icon

What is Opus Genetics Inc (IRD)'s earnings per share (EPS) for the last quarter?

Opus Genetics Inc. EPS for the last quarter amounts to -0.25 USD, decreased -13.79 % YoY.

arrow icon

What changes have occurred in the market's expectations for Opus Genetics Inc (IRD)'s fundamentals?

The market is revising Downward the revenue expectations for Opus Genetics, Inc. (IRD) for FY2025, with the revenue forecasts being adjusted by -3.6% over the past three months. During the same period, the stock price has changed by 75.59%.
arrow icon

How many employees does Opus Genetics Inc (IRD). have?

Opus Genetics Inc (IRD) has 18 emplpoyees as of December 05 2025.

arrow icon

What is Opus Genetics Inc (IRD) market cap?

Today IRD has the market capitalization of 153.79M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free